The Influence of Antiretroviral Therapy on Hepatitis C Virus Viral Load and Liver Fibrosis in Human Immunodeficiency Virus-Coinfected Patients: An Observational Study
- 27 November 2019
- journal article
- research article
- Published by S. Karger AG in Intervirology
- Vol. 62 (5-6) , 182-190
Abstract
Background: The role of antiretroviral therapy (ART) for Hepatitis C viral load (HCV-VL) and liver fibrosis is poorly understood. This study aimed at evaluating the influence of ART on HCV-VL and liver fibrosis in human immunodeficiency virus (HIV)/HCV-coinfected patients. Methods: We conducted a retrospective cohort study of HIV/HCV-coinfected patients followed at a tertiary university hospital. Results: In total, 143 patients were included. In 61 patients, ART initiation was accompanied by an increase in HCV-VL and a decrease in HIV viral load (HIV-VL), whereas ART suspension led to a decrease in HCV-VL and an increase in HIV-VL. Among the 55 HIV-suppressed patients who switched to a raltegravir (RAL)-containing regimen, median HCV-VL levels decreased significantly, while switching to a rilpivirine-containing regimen did not yield a significant reduction. Discussion: If the treatment of chronic hepatitis starts before ART, ART initiation should be delayed as much as possible. If ART has been started, it is advisable to wait 1 year before initiating chronic hepatitis treatment. RAL as the third agent in an ART regimen could be beneficial in HIV/HCV-coinfected patients, in comparison to other antiretroviral drugs. Conclusion: The start and the suspension of ART significantly interferes with HCV-VL in HIV/HCV-coinfected patients.Keywords
This publication has 40 references indexed in Scilit:
- Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general populationInternational Journal Of Clinical Practice, 2012
- Safety and efficacy of raltegravir in patients with HIV‐1 and hepatitis B and/or C virus coinfectionHIV Medicine, 2011
- Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteersJournal of Antimicrobial Chemotherapy, 2011
- Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damageAIDS, 2010
- Transient elastography: A non-invasive tool for assessing liver fibrosis in HIV/HCV patientsWorld Journal of Gastroenterology, 2010
- Review: Predicting the probable outcome of treatment in HCV patientsTherapeutic Advances in Gastroenterology, 2009
- Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive DrugsAmerican Journal of Transplantation, 2009
- Hepatitis C Virus Infection and the Risk of Coronary DiseaseClinical Infectious Diseases, 2009
- HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortalityBMC Public Health, 2009
- Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysisAIDS, 2008